Raven
7561 views
Rate Now: 1 2 3 4

average rating: 0.00 / 0 ratings
Created by Raven
DESCRIPTION:

Date updated:04-28-2007

Bio

symbol name last price % change open
  • +
  • POZN
    Pozen
  • $6.95
  • 0.00%
  • $N/A

Blockbuster (anticipated yearly sales of more than 1 Billion) Drug Candidates: 1. Trexima for migraines...August FDA decision. The analysts are expecting approval. Glaxo-Smith-Klein is the developmental/commercialization partner. PN 400 Arthritis medicine...Phase 3 trials to start this year. Astra Zeneca (375 million contract) is the developmental/commercialization partner. PA 325 Safer (in terms of gastrointestinal damage) Aspirin. Stellar results from the first study were released on March 6th.

People owning POZN also tend to own: ABPIACADAGIXAVGNCOLYDEPOMNTA

TheStreet.com Rating: D What is this?

  • +
  • DNDN
    Dendreon Corporat
  • $27.69
  • +1.80%
  • $27.39

40% short , it may not cure cancer ,but it surely can give a bit more time on earth and with a better qaulity of life. I have seen the effect of rediation, my fathrer died from it , and now my best friend is undergoing the same.

People owning DNDN also tend to own: GLWUNHACASAHMATBAUYBRLC

TheStreet.com Rating: D- What is this?

  • +
  • ISPH
    Inspire Pharmaceu
  • $5.22
  • 0.00%
  • $N/A

AzaSite been approved . Inspire expects to launch AzaSite in the latter end of the third quarter, and projects the product will generate $30 million to $45 million in 2008 sales . Much more potential !

People owning ISPH also tend to own: APKTARTGBBIBBYCEGECORTDNDN

TheStreet.com Rating: D What is this?

  • +
  • VION
    Vion
  • $0.00
  • N/A
  • $N/A

Recent accumulation by institution and insiders Vion has two agents in clinical trials. Cloretazine® (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine® (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies

People owning VION also tend to own: ABPIACADAGIXAVGNCOLYDEPOMNTA

TheStreet.com Rating: No Rating What is this?

  • +
  • ONXX
    Onyx Pharmaceutic
  • $28.63
  • +0.88%
  • $28.32

possible buy out? The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals

People owning ONXX also tend to own: AAADMCCRTCVXEWBCFMDMRO

TheStreet.com Rating: C What is this?

  • +
  • ONXX
    Onyx Pharmaceutic
  • $28.63
  • +0.88%
  • $28.32

possible buy out? The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals

People owning ONXX also tend to own: AAADMCCRTCVXEWBCFMDMRO

TheStreet.com Rating: C What is this?

  • +
  • ACEL
  • $0.00
  • 0.00%
  • $N/A

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial.

People owning ACEL also tend to own: AINVAMSWACYTREWZCBLILMRAMA

TheStreet.com Rating: No Rating What is this?

  • +
  • IDMI
  • $0.00
  • 0.00%
  • $N/A

Biopharmaceutical company IDM Pharma Inc. said Tuesday it will meet with a Food and Drug Administration advisory panel May 9 to discuss its application for Junovan. The drug -- its lead candidate -- is aimed at treating osteosarcoma, a type of malignant bone cancer, following surgical resection in combination with chemotherapy. IDM will meet with the Oncologic Drugs Advisory Committee, which will then give its recommendation to the FDA.

People owning IDMI also tend to own: EMRHSOAMASQUIXALTRCLRTCSCO

TheStreet.com Rating: No Rating What is this?

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Black Friday Short-Squeeze Oppor...

By Jonas Elmerraji Posted on Nov. 25, 2009 With Thanksgiving fast approaching, retailers have one thing on their collective minds: Black Friday. After all, the day, whi...

11.25.09 | 13:33 PM
Dividend Stocks for the Week

By Jonas Elmerraji Posted on Nov. 24, 2009 Don’t dismiss dividends right now. While stocks may have made significant strides in the rally that’s taken hold of the m...

11.24.09 | 11:36 AM
This Week's 'Barron's' Roundup

By Roberto Pedone Posted on Nov. 24, 2009 10 Terrific Dividend Stocks: This Barron’s article highlights 10 high-quality dividend-paying stocks for investors who’re ...

11.24.09 | 08:05 AM
Rocket Stocks for the Week

By Jonas Elmerraji Posted on Nov. 23, 2009 As well as broad-based indexes have performed in the last few months, Stockpickr's weekly Rocket Stocks list has managed to d...

11.23.09 | 10:34 AM
more articles
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
Wealth distribution by race and ...
11.23.08 | 18:44 PM From author Valerie J
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
more forums
Q. This is just a little bump in th...
11.27.09 | 10:38 AM Asked by stransmith

A. I sold my gold stock on this mood, this
is a sign of a financial bubble, one
burst leads speculators to predict
others. Time to diversify out of gold,
and into agricultural commodities.
Bought some BG, still have MOS.

today 's lists
Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more

Dogs of the Dow

Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on June 2, 2009. more

Rising on Unusual Volume

Here are some stocks that moved up on unusual volume on Nov. 24, 2009. more